Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study)
| العنوان: | Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study) |
|---|---|
| المؤلفون: | Tadahiro Shoji, Eriko Takatori, Takayuki Nagasawa, Masahiro Kagabu, Tsukasa Baba, Tatsuhiko Shigeto, Yukiko Matsumura, Dai Shimizu, Yukihiro Terada, Manabu Seino, Tsuyoshi Ohta, Satoru Nagase, Shogo Shigeta, Hideki Tokunaga, Muneaki Shimada, Michiko Kaiho-Sakuma, Shigenori Furukawa, Shu Soeda, Takafumi Watanabe, Fumiaki Takahashi, Yoshihito Yokoyama |
| المصدر: | International Journal of Clinical Oncology. 27:1874-1880 |
| بيانات النشر: | Springer Science and Business Media LLC, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Ovarian Neoplasms, Hematology, General Medicine, Progression-Free Survival, Bevacizumab, Oncology, Antineoplastic Combined Chemotherapy Protocols, Humans, Fallopian Tube Neoplasms, Female, Surgery, Neoplasm Recurrence, Local, Peritoneal Neoplasms, Fallopian Tubes, Retrospective Studies, Platinum |
| الوصف: | Outcomes with and without bevacizumab as first-line chemotherapy in Japanese-only ovarian cancer patients have not been reported. In this study, we report a retrospective study conducted at the Tohoku Gynecologic Cancer Unit.The study included 453 patients with stage III/IV ovarian, fallopian tube, and primary peritoneal cancer who received first-line platinum-based chemotherapy. The patients were divided into two groups: bevacizumab (168 patients) and without bevacizumab (285 patients). The primary endpoint was the rate of platinum-resistant recurrence and the secondary endpoints were the antitumor response, progression-free survival, overall survival, and adverse events.The objective response rates for patients with measurable diseases treated with and without bevacizumab were 84.5% and 73.0%, respectively (P = 0.0066). Platinum-resistant recurrence in the groups treated with and without bevacizumab was noted in 31 (18.4%) and 111 (38.6%) patients, respectively (P 0.0001). The median progression-free survival for the bevacizumab and without bevacizumab groups was 23 and 15 months, respectively (P = 0.0002), and the median overall survival was not reached and 49 months, respectively (P = 0.0005). Hypertension of grade 3 or higher was observed in 21 patients (12.5%) in the bevacizumab group (P 0.001), and proteinuria was observed in 18 patients (10.7%) and 1 patient (0.3%) in the bevacizumab and without bevacizumab groups, respectively (P 0.001). Intestinal perforation was observed in only one patient (0.6%) in the bevacizumab group.Combination and maintenance with bevacizumab in primary chemotherapy for advanced ovarian, fallopian tube, and primary peritoneal cancer was effective in reducing platinum-resistant recurrence rates and prolonging progression-free and overall survival. |
| تدمد: | 1437-7772 1341-9625 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e25dc08739652ee1fea35757be57c7f https://doi.org/10.1007/s10147-022-02246-1 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....0e25dc08739652ee1fea35757be57c7f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14377772 13419625 |
|---|